Abstract:Abstract Background mRNA modifications constitute ancient mechanisms in regulating gene expression after transcription. N6-methyladenosis (m6A), which is the most prevalent internal RNA modification, is not only installed by m6A methyltransferases, removed by demethylases, but also specifically bounded by RNA-binding proteins. As a significant component in the m6A methyltransferase complex, RNA binding motif protein 15 (RBM15) plays a vital role in m6A methylation. Nevertheless, its function and mechanism in myocardial infarction (MI) remain poorly defined. Purpose To investigate the role and mechanism of RBM15 in regulating its targets through m6A methylation in MI. The research results will not only add new content to the basic mechanism of myocardial protection but also provide new ideas and new targets for the prevention and treatment of MI. Methods Liquid chromatography-tandem mass spectrometry (LC-MS/MS) was used to clarify the total m6A level, and Reverse transcription quantitative real-time PCR (RT-qPCR) and Western blot were used to determine the expression of RBM15 in normal and MI tissues. Then the effects of RBM15 on cardiomyocytes were clarified using apoptosis assay, and cell proliferation assay. Methylated RNA immunoprecipitation sequencing (MeRIP-seq), and transcriptomic RNA sequencing (RNA-seq) were used to perform the regulator mechanism of RBM15 on target gene Thbs4 in MI. Results In this research, we showed that total m6A methylation was increased in MI, and RBM15 was a main factor involved with this process. Silencing RBM15 remarkably decreased cell proliferation and increased apoptosis in vitro, and resulted in severe cardiac remodeling and further exacerbation of cardiac dysfunction in vivo, whereas its overexpression caused the opposite effects. Then, Thbs4 was identified as a direct downstream target of RBM15, and RBM15 induced m6A methylation on the 3'UTR of Thbs4 pre-mRNA. We also found that it showed faster Thbs4 mRNA decay and exhibited decreased mRNAs and levels of protein expression in RBM15-deficient cardiomyocytes under hypoxia. Furthermore, we confirmed that RBM15 contributed significantly to regulate the PI3k/Akt pathway. Conclusions Our work uncovers a complex RBM15-Thbs4-PI3K/Akt regulatory model based on m6A methylation and provides a new insight into the epi-transcriptomic dysregulation in MI development. Funding Acknowledgement Type of funding source: Public grant(s) – National budget only. Main funding source(s): National Natural Science Foundation of China

RBM15 condensates modulate m 6 A modification of STYK1 to promote tumorigenesis

RBM15 Promotes Hepatocellular Carcinoma Progression by Regulating N6-methyladenosine Modification of YES1 Mrna in an IGF2BP1-dependent Manner.

RBM15 facilitates laryngeal squamous cell carcinoma progression by regulating TMBIM6 stability through IGF2BP3 dependent

RNA methylase RBM15 facilitates malignant progression of colorectal cancer through regulating E2F2 in an m6A modification‐dependent manner

Epigenetic activation of RBM15 promotes clear cell renal cell carcinoma growth, metastasis and macrophage infiltration by regulating the m6A modification of CXCL11

RBM15B Promotes Prostate Cancer Cell Proliferation via PCNA m6A Modification

Abstract 3087: The m6A methyltransferase RBM15 drives the growth of triple-negative breast cancer cells through the stimulation of serine and glycine metabolism

RBM10 regulates the tumorigenic potential of human cancer cells by modulating PPM1B and YBX1 activities

N6-Methyladenosine Methylation Regulator RBM15 is a Potential Prognostic Biomarker and Promotes Cell Proliferation in Pancreatic Adenocarcinoma

YY1-Targeted RBM15B Promotes Hepatocellular Carcinoma Cell Proliferation and Sorafenib Resistance by Promoting TRAM2 Expression in an M6a-Dependent Manner

RNA demethylase ALKBH5 promotes tumorigenesis in multiple myeloma via TRAF1-mediated activation of NF-κB and MAPK signaling pathways

Knockdown of RBM15 inhibits tumor progression and the JAK-STAT signaling pathway in cervical cancer

RBM15 drives the progression of lung adenocarcinoma by regulating N6-methyladenosine-mediated LDHA mRNA stability

RBM5 suppresses proliferation, metastasis and glycolysis of colorectal cancer cells via stabilizing phosphatase and tensin homolog mRNA

Global RNA Interaction and Transcriptome Profiles Demonstrate the Potential Anti-Oncogenic Targets and Pathways of RBM6 in HeLa Cells

Knockdown RBM15 Inhibits Colorectal Cancer Cell Proliferation and Metastasis Via N6-Methyladenosine (m6a) Modification of MyD88 Mrna.

M6a Methyltransferase Rbm15 Promotes Cardiomyocytes Survival Under Hypoxia By Increasing Thbs4 Rna Methylation And Mediating Pi3k/Akt Signaling

Identification of RBM15 as a prognostic biomarker in prostate cancer involving the regulation of prognostic m6A-related lncRNAs

RBM33 is a Unique M6a RNA-binding Protein That Regulates ALKBH5 Demethylase Activity and Substrate Selectivity

RNA demethylase ALKBH5 promotes colorectal cancer progression by posttranscriptional activation of RAB5A in an m6A‐YTHDF2‐dependent manner

The m6A demethylase ALKBH5 promotes tumor progression by inhibiting RIG-I expression and interferon alpha production through the IKKε/TBK1/IRF3 pathway in head and neck squamous cell carcinoma